[前列腺特异性抗原在前列腺癌早期诊断中的价值]

[Value of prostate specific antigen in early diagnosis of prostatic cancer].

作者信息

Xiao Li-Ping, Bi Xiang-Jun, Li Ya-Nan, Chen Xiao-Qing, Zhang Xiao-Feng, Yu Xin-Pei, Liu Gang, Yang Ming-Chang, Song Zhou

机构信息

Second Department of Geriatrics, Guangzhou General Hospital of Guangzhou Command, Guangzhou 510010, China.

出版信息

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Jan;27(1):107-8, 112.

DOI:

PMID:17259162

Abstract

OBJECTIVE

To evaluate the value of serum prostate specific antigen (PSA), free PSA (FPSA) and PSA density (PSAD) in early diagnosis of prostatic cancer.

METHODS

Sixty-eight patients with benign prostate hyperplasia (BPH), 28 with prostatic intraepithelial neoplasia (PIN) without canceration, and 32 with prostatic cancer, all diagnosed by prostatic biopsy, were enrolled in this study. Serum PSA and FPSA were measured and FPSA/PSA ratio and PSAD calculated for each patient, and the data analyzed to explore the association of these indices with prostatic cancer.

RESULTS

Serum PSA level and PSAD were markedly different between the cancer patients and non-cancer patients (P<0.001 and P<0.01, respectively). FPSA/PSA ratio also differed between them (P<0.05). The same results were also found between BPH and cancer patients. Significant difference was noted in serum PSA and PSAD between PIN and cancer patients (P<0.01), but not in FPSA/PSA ratio (P>0.05). No marked difference was observed in serum PSA, FPSA/PSA ratio and PSAD between BPH and PIN patients.

CONCLUSION

Serum PSA provides a very important clue for early diagnosis of prostatic cancer, and more accurate diagnosis can be obtained by considering also FPSA/PSA ratio. PSAD may also assist in the early diagnosis of prostatic cancer.

摘要

目的

评估血清前列腺特异性抗原（PSA）、游离PSA（FPSA）和PSA密度（PSAD）在前列腺癌早期诊断中的价值。

方法

本研究纳入了68例经前列腺活检确诊为良性前列腺增生（BPH）的患者、28例未发生癌变的前列腺上皮内瘤变（PIN）患者以及32例前列腺癌患者。检测每位患者的血清PSA和FPSA，并计算FPSA/PSA比值和PSAD，对数据进行分析以探讨这些指标与前列腺癌的相关性。

结果

癌症患者与非癌症患者之间的血清PSA水平和PSAD存在显著差异（分别为P<0.001和P<0.01）。他们之间的FPSA/PSA比值也有所不同（P<0.05）。在BPH患者和癌症患者之间也发现了相同的结果。PIN患者与癌症患者之间的血清PSA和PSAD存在显著差异（P<0.01），但FPSA/PSA比值无显著差异（P>0.05）。BPH患者和PIN患者之间的血清PSA、FPSA/PSA比值和PSAD未观察到明显差异。